Attovia Therapeutics, Inc. (ATTO) stock
ATTONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026
$14.86+0.13 (+0.92%)
Close on Nov 17, 2026Market cap $678.38MP/E –Yield –
Attovia Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $20.29M | – |
| Q2 FY2026 | Jun 30, 2026 | $18.95M | – |
| Q3 FY2025 | Sep 30, 2025 | $12.32M | – |
| Q2 FY2025 | Jun 30, 2025 | $13.59M | – |
See a number that looks wrong?